Medicines Co., SciClone deal

The Medicines Co. granted SciClone exclusive rights to promote cardiovascular drugs Cleviprex clevidipine and Angiomax bivalirudin

Read the full 162 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE